MétaCan
Menu
Back to cohort
Record W6980850156

Cost-effectiveness of Rifaximin treatment in patients with advanced fibrosis who maintain excessive alcohol consumption.

2021· dissertation· en· W6980850156 on OpenAlex

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

affAt least one author lists a Canadian institution in the pinned OpenAlex snapshot.

Bibliographic record

VenueDuo Research Archive (University of Oslo) · 2021
Typedissertation
Languageen
FieldNursing
TopicNuts composition and effects
Canadian institutionsInstitute of Health Economics
Fundersnot available
KeywordsRifaximinRandomized controlled trialFibrosisLiver diseaseClinical endpointDiseaseClinical trial
DOInot available

Abstract

fetched live from OpenAlex

Background & aimsThe ability of Rifaximin to modulate gut microbiota makes it the first potential treatment for early stages of alcohol-related liver disease (ALD)-i.e., advanced fibrosis and compensated cirrhosis.The present study aims to investigate what effect Rifaximin treatment has to have in order to be cost-effective. MethodsA partitioned survival model was developed to simulate a sample of ongoing excessive drinkers with advanced fibrosis (F3-4) over their lifetime.The costs (in 2021 US$) and benefits in terms of quality-adjusted life years (QALYs) gained were estimated from the healthcare perspective.The corresponding healthcare costs were taken from the Danish DRG.The OS and PFS curves were based on the data from the GALA-ALD natural history data, and utilities were estimated from the previously published studies.We estimated what effect Rifaximin treatment has to have in order to be a cost-effective treatment option.Furthermore, we conducted deterministic and scenario analysis, as well as one-way and probabilistic sensitivity analysis to investigate the impact of parameter uncertainty, and value of information analysis was performed to estimate the value of further clinical research aiming to reduce decision uncertainty. ResultsCompared to the standard care, Rifaximin treatment was found to be cost-effective at a willingness-to-pay threshold (WTP) of $48,000 (equivalent of 40,000) per QALY if the intervention increases the disease-free survival (DFS) by at least 3.7%.3.7% is the pivot point for cost-effectiveness, therefore, the higher the Rifaximin effect is, the higher are the chances that it will be cost-effective.The results of our sensitivity and scenario analysis confirmed robustness of the main findings. ConclusionsIt is important to prevent progression of early ALD disease which, upon reaching the stage of decompensated cirrhosis, is considered to be irreversible and is associated with very high costs and mortality rates. LAY SUMMARYRifaximin can improve the outcomes of ongoing excessive drinkers with advanced fibrosis (F3-4) by delaying or preventing the transition of these patients to decompensation and, subsequently, death state.A wider use of Rifaximin treatment should be determined based on the outcomes from Rifaximin clinical trial and evaluation of whether or not the intervention increases DFS by at least 3.7%.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.659
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.035
GPT teacher head0.322
Teacher spread0.287 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it